NextCure (NASDAQ:NXTC) Releases Earnings Results, Beats Expectations By $1.45 EPS

NextCure (NASDAQ:NXTC) issued its quarterly earnings results on Thursday. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $1.45, FiscalAI reports.

NextCure Trading Up 1.3%

NASDAQ:NXTC traded up $0.16 during trading hours on Thursday, reaching $12.76. The company had a trading volume of 76,139 shares, compared to its average volume of 34,617. NextCure has a 52 week low of $2.69 and a 52 week high of $15.74. The firm has a market cap of $44.79 million, a price-to-earnings ratio of -0.53 and a beta of 1.50. The firm’s 50 day moving average price is $12.70 and its 200-day moving average price is $10.01.

Hedge Funds Weigh In On NextCure

Institutional investors and hedge funds have recently modified their holdings of the company. Cable Car Capital LP lifted its position in shares of NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after buying an additional 88,040 shares in the last quarter. Geode Capital Management LLC increased its holdings in NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares in the last quarter. Renaissance Technologies LLC raised its stake in NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after acquiring an additional 5,300 shares during the period. Exome Asset Management LLC bought a new stake in NextCure during the 4th quarter worth approximately $2,341,000. Finally, AWM Investment Company Inc. purchased a new position in NextCure during the fourth quarter valued at approximately $1,665,000. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a research note on Wednesday, January 28th. Wall Street Zen raised shares of NextCure to a “hold” rating in a research report on Saturday, December 13th. Finally, LADENBURG THALM/SH SH raised NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Friday, November 7th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, NextCure has an average rating of “Moderate Buy” and a consensus price target of $23.00.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.